Essential Premium

Hedge Funds Cash in on Rare IPO

The IPO market has been slow, but biotech firm Evommune is a bright spot, with its share price up more than 21 percent since going public on November 5.

QMS Diversified Global Macro Defied the CTA Trend

Managed futures have been struggling all year, but QMS Diversified Global Macro has climbed almost 30 percent for the year despite a small loss in October. 

Sponsored

The Shifting Value Dynamics Between Winter Wheats

Opinion: How Passive Investing Has Pressured IPOs, Stifled Innovation, and Fueled Manias Like Meme Stocks

Investors are increasingly focused only on the major benchmarks, hollowing out the IPO pipeline of earlier-stage, high-growth companies.

Related Content

IPO Hopes Rise for Biopharma Investors

Stephen Taub

AI Meets Biotech — and Hedge Funds Are Buying In

Stephen Taub

Inside Greg Fleming’s Partnership with Viking Global and the Rockefeller Family

Ted Seides

SPONSORED BY CME GROUP

Is the Market Really Sure About Its Direction?

CME Group Economist Dr. Mark Shore covers the two volatility metrics that together provide a fuller picture of market sentiment.

How Fed Policy Can Impact Corporate Bond Spreads

Since the Federal Reserve’s rate cut, options-adjusted spreads are nearing historical lows. What does this shift reveal about investor sentiment?

As U.S. Stocks Hit Records, Do Mexican Equities Offer Diversification Opportunities?

The U.S. stock market is setting records, but what about Mexico? Why Mexican stocks could be a valuable addition to a portfolio.

1270 Avenue of the Americas, Suite 1100

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site. Institutional Investor is part of Delinian.

 

| Unsubscribe

LinkedIn
X (Twitter)
Bluesky
Instagram